بررسی شیوع عوامل خطر پوکی استخوان، در زنان یائسه کمتر از 65 سال مراجعه‌کننده به بیمارستان الزهرا(س)

نوع مقاله : Original Article(s)

نویسندگان

1 دانشجوی پزشکی، دانشکده‌ی پزشکی، دانشگاه علوم پزشکی اصفهان، اصفهان، ایران

2 دانشیار، گروه روماتولوژی، دانشکده‌ی پزشکی، دانشگاه علوم پزشکی اصفهان، اصفهان، ایران

3 استاد، گروه روماتولوژی، دانشکده‌ی پزشکی، دانشگاه علوم پزشکی اصفهان، اصفهان، ایران

چکیده

مقاله پژوهشی




مقدمه: کاهش تراکم مواد معدنی در استخوان، باعث کاهش مقاومت مکانیکی استخوان‌ها می‌شود و این روند بتدریج، منجر به پیدایش پوکی استخوان می‌گردد. در خانم‌ها هنگام بارداری به علت برداشت کلسیم و سایر مواد معدنی از استخوان‌ها و پس از یائسگی، بدلیل کاهش ترشح استروژن، پوکی استخوان و شکستگی شایع‌تر از مردان دیده می‌شود. مطالعه‌ی حاضر به منظور، بررسی عوامل خطر پوکی استخوان، در خانم‌های یائسه صورت گرفت.
روش‌ها: از بین خانم‌های کمتر از 65 سالی که طی سال‌های 1397 و 1398 به منظور بررسی تراکم استخوان به بیمارستان الزهرا(س) اصفهان مراجعه کرده بودند، پرونده‌ی پزشکی 384 نفر مورد بررسی قرار گرفت. اطلاعات لازم با استفاده از چک‌لیست‌هایی که حاوی اطلاعات دموگرافیک بیماران شامل سن، قد، وزن، سن یائسگی، سن اولین قاعدگی، بیماری‌های زمینه‌ای (هایپرتیروئیدی، بیماری انسدادی مزمن ریه، نارسایی کلیه، دیابت نوع یک، هایپرپاراتیروئیدی اولیه، پرولاکتینما)، مصرف الکل، مصرف سیگار، مصرف کورتیکو استروئید، لووتیروکسین، داروهای ضد انعقاد خون و فعالیت بدنی بودند جمع‌آوری شد.
یافته‌ها: یافته‌های این پژوهش نشان می‌دهند که، T-Score سنجش تراکم استخوان بیماران، با مصرف کورتیکو استروئیدها (1/17 ± 4071/1-)، لووتیروکسین
(1/49 ± 9441/1-)، سیگار (0/3876 ± 6421/1- ) و بیماری‌های زمینه‌ای (1/2 ± 4511/1-) رابطه‌ی معنی‌داری در کاهش تراکم استخوان داشت (0/05 > P).
نتیجه‌گیری: از آن‌جا که کاهش تراکم استخوان می‌تواند منجر به موربیدیتی و مورتالیتی گردد، بخصوص در افراد با مصرف طولانی کورتیکو استروئید، لووتیروکسین، سیگار و نیز داشتن بیماری‌های زمینه‌ای، نداشتن فعالیت بدنی مناسب (50 درصد)، کهنسالی و بانوانی که باردارهای‌های مکرر را تجربه می‌نمایند، توجه ویژه‌ای در خصوص پایش تراکم استخوان و درمان به موقع آن نیاز دارند.

تازه های تحقیق

بهرام پاکزاد:  Google Scholar, PubMed

منصور کریمی فر: Google Scholar, PubMed

 

کلیدواژه‌ها

موضوعات

عنوان مقاله [English]

Investigating the Prevalence of Osteoporosis Risk Factors in Postmenopausal Women Less Than 65 Years of Age Referring to Al-Zahra Hospital

نویسندگان [English]

  • Sajede Sojudi 1
  • Farshid Saberi 1
  • Bahram Pakzad 2
  • Mansoor Karimifar 3
1 Medical Student, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
2 Associated Professor of Rheumatology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
3 Professor of Rheumatology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
چکیده [English]

Background: Decreased bone mineral density (BMD) reduces the mechanical resistance of bones, and this process gradually leads to osteoporosis. In women, osteoporosis and fractures are more common than men during pregnancy due to calcium and other minerals being removed from the bones and after menopause due to the decrease in estrogen secretion. The present study was conducted to investigate the risk factors of osteoporosis in postmenopausal women.
Methods: Among women under 65 who visited Al-Zahra Hospital in Isfahan during 2017 and 2018 to check for BMD, the medical records of 384 people were examined. Necessary information using checklists that contain demographic information of patients including, age, height, weight, age of menopause, age of first menstruation, underlying diseases (hyperthyroidism, chronic obstructive pulmonary disease, renal failure, type 1 diabetes mellitus, primary hyperparathyroidism, prolactinoma), alcohol consumption, smoking, corticosteroid, levothyroxine, anticoagulants drugs use and reduced physical activity were collected.
Findings: The findings of this research show that the T-Score of measuring the bone density of patients with the use of corticosteroids (-1.4071 ± 1.17), levothyroxine (-1.9441 ± 1.49), smoking (-1.6421 ± 0.3876) and underlying diseases (-1.4511 ± 1.2) had a significant relationship in reducing bone density (P < 0.05).
Conclusion: Since BMD reduction can lead to morbidity and mortality, especially in people with long-term use of corticosteroids, levothyroxine, smoking, as well as underlying diseases, lack of proper physical activity (50%), old age, and women who experience frequent pregnancies, need special attention, regarding BMD monitoring and timely treatment.

کلیدواژه‌ها [English]

  • Osteoporosis
  • Menopause
  • Bone density

مراجع

  1. Gkastaris K, Goulis DG, Potoupnis M, Anastasilakis AD, Kapetanos G. Obesity, osteoporosis and bone metabolism. J Musculoskelet Neuronal Interact 2020; 20(3): 372-81.
  2. Kim B, Cho YJ, Lim W. Osteoporosis therapies and their mechanisms of action. Exp Ther Med 2021; 22(6): 1379.
  3. Ebeling PR, Nguyen HH, Aleksova J, Vincent AJ, Wong P, Milat F. Secondary osteoporosis. Endocr Rev 2022; 43(2): 240-313.
  4. Özmen E, Biçer O, Bariş A, Circi E, Yüksel S, Beytemür O, Kesiktaş FN. Improving osteoporosis prediction using vertebral bone quality score and paravertebral muscle measurements from lumbar MRI scans. Clin Spine Surg 2024; 37(8): 357-63.
  5. Watanabe R, Shiraki M, Saito M, Okazaki R, Inoue D. Restrictive pulmonary dysfunction is associated with vertebral fractures and bone loss in elderly postmenopausal women. Osteoporos Int 2018; 29(3): 625-33.
  6. Reid IR, Bolland MJ. Calcium and/or Vitamin D Supplementation for the Prevention of Fragility Fractures: Who Needs It? Nutrients 2020; 12(4): 1011.
  7. Roberts SB, Silver RE, Das SK, Fielding RA, Gilhooly CH, Jacques PF, et al. Healthy aging-nutrition matters: start early and screen often. Adv Nutr 2021; 12(4): 1438-48.
  8. Lee WC, Guntur AR, Long F, Rosen CJ. Energy Metabolism of the osteoblast: implications for osteoporosis. Endocr Rev 2017; 38(3): 255-66.
  9. He B, Lyu Q, Yin L, Zhang M, Quan Z, Ou Y. Depression and Osteoporosis: A Mendelian Randomization Study. Calcif Tissue Int 2021; 109(6): 675-84.
  10. Kashfi SS, Abdollahi G, Hassanzadeh J, Mokarami H, Khani Jeihooni A. The relationship between osteoporosis and depression. Sci Rep 2022; 12(1): 11177.
  11. Cizza G, Primma S, Csako G. Depression as a risk factor for osteoporosis. T Trends Endocrinol Metab 2009; 20(8): 367-73.
  12. Cheng C-H, Chen L-R, Chen K-H. Osteoporosis due to hormone imbalance: an overview of the effects of estrogen deficiency and glucocorticoid overuse on bone turnover. Int J Mol Sci 2022; 23(3): 1376.
  13. Adler RA. Osteoporosis in men. Osteoporosis: Pathophysiology and Clinical Management. New York, NY: SpringerLink; 2010. p. 391-406.
  14. Nicoli F, Dito G, Guabello G, Longhi M, Corbetta S. Hypercalciuria in postmenopausal women with reduced bone mineral density is associated with different mineral metabolic profiles: effects of treatment with thiazides and anti-resorptives. Front Med (Lausanne) 2021; 8: 780087.
  15. Xu N, Wang Y, Xu Y, Li L, Chen J, Mai X, et al. Effect of subclinical hyperthyroidism on osteoporosis: A meta-analysis of cohort studies. Endocrine 2020; 69(1): 39-48.
  16. Inoue D, Inoue R. Mechanisms of osteoporosis associated with chronic obstructive pulmonary disease. J Bone Miner Metab 2024: 42(4): 428-37.
  17. Hsu C-Y, Chen L-R, Chen K-H. Osteoporosis in patients with chronic kidney diseases: a systemic review. Int J Mol Sci 2020; 21(18): 6846.
  18. Halper-Stromberg E, Gallo T, Champakanath A, Taki I, Rewers M, Snell-Bergeon J, et al. Bone mineral density across the lifespan in patients with type 1 diabetes. The J Clin Endocrinol Metab 2020; 105(3): 746-53.
  19. Cormier C, Koumakis E. Bone and primary hyperparathyroidism. Joint Bone Spine 2022; 89(1): 105129.
  20. Auriemma RS, Pirchio R, Pivonello C, Garifalos F, Colao A, Pivonello R. Approach to the patient with prolactinoma. J Clin Endocrinol Metab 2023; 108(9): 2400-23.
  21. Yong E-L, Logan S. Menopausal osteoporosis: screening, prevention and treatment. Singapore Med J 2021; 62(4): 159-66.
  22. Godos J, Giampieri F, Chisari E, Micek A, Paladino N, Forbes-Hernández TY, et al. Alcohol consumption, bone mineral density, and risk of osteoporotic fractures: a dose–response meta-analysis. Int J Environ Res Public Health 2022; 19(3): 1515.
  23. Fahimfar N, Noorali S, Yousefi S, Gharibzadeh S, Shafiee G, Panahi N, et al. Prevalence of osteoporosis among the elderly population of Iran. Arch Osteoporos 2021; 16: 16.
  24. Hassanzadeh J, Nasimi B, Ranjbar Omrani G, Moradi Nazar M, Mohammadbeigi A. Evaluating the quality of life of osteoporotic postmenopausal women [in Persian]. Iranian J Endocrinol Metabol 2012; 14(3): 234-40.
  25. Fallah Mehrabadi E, Pakgohar M, Asadi S, Haghani H. Lifestyle of elderly people with osteoporosis and its related factors [in Persian]. Salmand: Iranian Journal of Ageing 2017; 12(2): 132-45.
  26. Keramat A, Khalilifard A, Adibi H, Chopra A, Kunjir V, Patwardhan B, et al. Association between demographic factors and osteoporosis in urban Iranian postmenopausal women. J Reprod Infertil 2005; 6(1): 98-106.
  27. Ayers C, Kansagara D, Lazur B, Fu R, Kwon A, Harrod C. Effectiveness and safety of treatments to prevent fractures in people with low bone mass or primary osteoporosis: a living systematic review and network meta-analysis for the American College of Physicians. Ann Intern Med 2023; 176(2): 182-95.
  28. Hawkins F, Garla V, Allo G, Males D, Mola L, Corpas E. Senile and postmenopausal osteoporosis: Pathophysiology, diagnosis, and treatment. In: Endocrinology of aging. Amsterdam, Netherlands, Elsevier; 2021. p. 131-69.
  29. Bauer DC. Osteoporosis Treatment After Hip Fracture: Bad News and Getting Worse. JAMA Netw Open 2018; 1(3): e180844.
  30. Guzon-Illescas O, Perez Fernandez E, Crespí Villarias N, Quirós Donate FJ, Peña M, Alonso-Blas C, et al. Mortality after osteoporotic hip fracture: incidence, trends, and associated factors. J Orthop Surg Res 2019; 14(1): 203.
  31. Cummings SR, Lui L-Y, Eastell R, Allen IE. Association between drug treatments for patients with osteoporosis and overall mortality rates: a meta-analysis. JAMA Intern Med 2019; 179(11): 1491-500.
  32. Sattui SE, Saag KG. Fracture mortality: associations with epidemiology and osteoporosis treatment. Nat Rev Endocrinol 2014; 10(10): 592-602.
  33. Li J, Chen X, Lu L, Yu X. The relationship between bone marrow adipose tissue and bone metabolism in postmenopausal osteoporosis. Cytokine Growth Factor Rev 2020; 52: 88-98.
  34. Khosla S, Melton 3rd LJ, Riggs BL. The unitary model for estrogen deficiency and the pathogenesis of osteoporosis: is a revision needed? J Bone Miner Res 2011; 26(3): 441-51.
  35. Haarhaus M, Evenepoel P, Disorder B, European Renal Osteodystrophy (EUROD) workgroup, Chronic Kidney Disease Mineral and Bone Disorder (CKD-MBD) working group of the European Renal Association–European Dialysis and Transplant Association (ERA-EDTA). Differentiating the causes of adynamic bone in advanced chronic kidney disease informs osteoporosis treatment. Kidney Int 2021; 100(3): 546-58.
  36. Pepe J, Body J-J, Hadji P, McCloskey E, Meier C, Obermayer-Pietsch B, et al. Osteoporosis in premenopausal women: a clinical narrative review by the ECTS and the IOF. J Clin Endocrinol Metab 2020; 105(8): 2487-506.
  37. Raterman HG, Bultink IE, Lems WF. Current treatments and new developments in the management of glucocorticoid-induced osteoporosis. Drugs 2019; 79(10): 1065-87.
  38. Ko Y-J, Kim JY, Lee J, Song H-J, Kim J-Y, Choi N-K, Park B-J. Levothyroxine dose and fracture risk according to the osteoporosis status in elderly women. J Prev Med Public Health 2014; 47(1): 36-46.
  39. Signorelli SS, Scuto S, Marino E, Giusti M, Xourafa A, Gaudio A. Anticoagulants and osteoporosis. Int J Mol Sci 2019; 20(21): 5275.
  40. Hardcastle SA, Yahya F, Bhalla AK. Pregnancy-associated osteoporosis: a UK case series and literature review. Osteoporos Int 2019; 30(5): 939-48.
  41. Bijelic R, Milicevic S, Balaban J. Risk factors for osteoporosis in postmenopausal women. Med Arch 2017; 71(1): 25-8.
  42. Schnatz PF, Marakovits KA, O'Sullivan DM. Assessment of postmenopausal women and significant risk factors for osteoporosis. Obstet Gynecol Surv 2010; 65(9): 591-6.
  43. Demir B, Haberal A, Geyik P, Baskan B, Ozturkoglu E, Karacay O, Deveci S. Identification of the risk factors for osteoporosis among postmenopausal women. Maturitas 2008; 60(3-4): 253-6.
  44. Martinez Perez JA, Palacios S, García FC, Pérez

    Assessing osteoporosis risk factors in Spanish menopausal women. Gynecol Endocrinol 2011; 27(10): 807-13.
  45. Jiang X, Qi X, Xie C. Lactobacillus plantarum LP45 inhibits the RANKL/OPG signaling pathway and prevents glucocorticoid-induced osteoporosis. Food Nutr Res 2023; 67.
  46. Vondracek SF, Hansen LB, McDermott MT. Osteoporosis risk in premenopausal women. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 2009; 29(3): 305-17.
  47. Thulkar J, Singh S, Sharma S, Thulkar T. Preventable risk factors for osteoporosis in postmenopausal women: Systematic review and meta-analysis. J Midlife Health 2016; 7(3): 108-13.

 

مجله دانشکده پزشکی اصفهان
دوره 42، شماره 776
هفته 4، شهریور
مرداد و شهریور 1403
صفحه 633-642

فایل ها

سابقه مقاله

  • تاریخ دریافت: 19 دی 1402
  • تاریخ پذیرش: 01 آبان 1403

هم رسانی

ارجاع به این مقاله

آمار